Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: Studies in an in vitro model

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 954-959

  Tonda, Raúl ^a   Galán, Ana María ^a   Pino, Marcos ^a   Cirera, Isabel ^a   Bosch, Jaume ^a   Hernández, María Rosa ^a   Ordinas, Antonio ^a   Escolar, Ginés ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Activated recombinant factor VII (rFVIIa); Cirrhosis; Hemostasis; Procoagulant action

Indexed keywords

FIBRIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBRIN FORMATION; HEMOSTASIS; HUMAN; IN VITRO STUDY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBENDOTHELIUM; THROMBOCYTE;

EID: 0346243791     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00454-9     Document Type: Article

References (41)

1. Paramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993;19:184-190.
2. Younger HM, Hadoke PW, Dillon JF, Hayes PC. Platelet function in cirrhosis and the role of humoral factors. Eur J Gastroenterol Hepatol 1997;9:989-992.
3. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002;22:83-96.
4. Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996;24:1137-1142.
5. Pagliaro L, Damico G, Sorensen TIA, Lebrec D, Burroughs AK, Morabito A, et al. Prevention of first bleeding in cirrhosis - a meta-analysis of randomized trials of non-surgical treatment. Ann Intern Med 1992;117:59-70.
6. Chung S. Management of bleeding in the cirrhotic patient. J Gastroenterol Hepatol 2002;17:355-360.
7. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114-124.
8. Bernstein D. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis. Semin Thromb Hemost 2000;26:437-438.
9. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000;11(Suppl. 1):S69-S74.
10. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-179.
11. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131-139.
12. Lisman T, Leebeek FW, Meijer K, van der MJ, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002;35:616-621.
13. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973;5:167-179.
14. Turitto VT, Weiss HJ, Baumgartner HR. Decreased platelet adhesion on vessel segments in von Willebrand's disease: a defect in initial platelet attachment. J Lab Clin Med 1983;102:551-564.
15. Ruggeri ZM. Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost 1993;70:119-123.
16. Galan AM, Tonda R, Altisent C, Maragall S, Ordinas A, Escolar G. Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model. Semin Hematol 2001;38:10-14.
17. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001;36:1081-1085.
18. Escolar G, Galan AM, Mazzara R, Castillo R, Ordinas A. Measurement of platelet interactions with subendothelial substrata: relevance to transfusion medicine. Transfus Med Rev 2001;15:144-156.
19. Escolar G, Mazzara R, White JG, Castillo R, Ordinas A. Contribution of perfusion techniques to the evaluation of the hemostatic effectiveness of platelet concentrates. Blood Cells 1992;18:403-415.
20. Escolar G, Mazzara R, Castillo R, Ordinas A. The role of the baumgartner technique in transfusion medicine: research and clinical applications. Transfusion 1994;34:542-549.
21. Monteagudo J, Reverter JC, Pereira A, Pijoan J, Balust J, Escolar G, et al. Prothrombin fragment-1 + 2 and thrombin-antithrombin complex measurements indicate continuous and progressive intraoperative thrombin generation in liver transplantation. Haemostasis 1993;23:51-57.
22. Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989;32:232-234.
23. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26:159-164.
24. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996;75:981-982.
25. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94:3951-3953.
26. D'orion R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, et al. Use of recombinant factor VIIa in 3 patients with inherited type I glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000;83:644-647.
27. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-1937.
28. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
29. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost 1998;80:578-584.
30. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988;71:629-635.
31. Weiss HJ, Hoffmann T, Turitto VT, Nemerson Y. Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries. Thromb Res 1994;73:313-326.
32. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003;1:1158-1160.
33. Swords NA, Mann KG. The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb 1993;13:1602-1612.
34. Galán AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003;43:885-892.
35. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547.
36. Hoffman M, Monroe D. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003;49:14-21.
37. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIbbeta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003;101:1864.
38. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476.
39. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S, Hathirat P. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000;11(Suppl. 1):S101-S105.
40. Testa G, Malago M, Broelsch CE. Bleeding problems in patients undergoing segmental liver transplantation. Blood Coagul Fibrinolysis 2000;11:S81-S85.
41. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003;1:1215-1219.